EPIX Medical, Inc.

Phase I clinical trial initiated for EP-2104R

Published in Physician Law Weekly, September 8th, 2004

EPIX Medical, Inc., (EPIX), a developer of pharmaceuticals for magnetic resonance imaging (MRI), has initiated its first human clinical trial of EP-2104R, an injectable MRI contrast agent which specifically targets blood clots, or thrombi, in the body.

EP-2104R binds selectively to fibrin, an important component of thrombus, and is designed to provide a bright MR image to allow the detection of small clots in arteries and veins, many of which may be undetectable with currently available imaging methods. Early thrombus detection may enable better therapeutic decision-making for patients with cardiovascular disease. The trial will be conducted in the U.S. under a U.S....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Physician Law Weekly

Source: Physician Law Weekly (2004-09-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry